scholarly journals The timing of liver resection in patients with colorectal cancer and synchronous liver metastases: a population-based study of current practice and survival

2018 ◽  
Vol 20 (6) ◽  
pp. 486-495 ◽  
Author(s):  
A. E. Vallance ◽  
J. van der Meulen ◽  
A. Kuryba ◽  
S. C. Charman ◽  
I. D. Botterill ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Resection ◽  
Liver Metastases ◽  
Current Practice ◽  
Population Based ◽  
Population Based Study ◽  
Synchronous Liver Metastases ◽  
Timing Of Liver Resection

scholarly journals The Impact of a Hepatobiliary Multidisciplinary Team Assessment in Patients with Colorectal Cancer Liver Metastases: A Population‐Based Study

2017 ◽  
Vol 22 (9) ◽  
pp. 1067-1074 ◽  
Author(s):  
Jennie Engstrand ◽  
Nikolaos Kartalis ◽  
Cecilia Strömberg ◽  
Mats Broberg ◽  
Anna Stillström ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Multidisciplinary Team ◽  
Population Based ◽  
Colorectal Cancer Liver Metastases ◽  
Population Based Study ◽  
Team Assessment ◽  
The Impact

Cost Analysis of Simultaneous vs Staged Resection of Colorectal Cancer Liver Metastases: A Population Based Study

2019 ◽  
Vol 229 (4) ◽  
pp. S56
Author(s):  
Julian Wang ◽  
Sameer Parpia ◽  
Chu-Shu Gu ◽  
Amiram Gafni ◽  
Pablo E. Serrano Aybar ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cost Analysis ◽  
Liver Metastases ◽  
Population Based ◽  
Colorectal Cancer Liver Metastases ◽  
Population Based Study

The impact of histologic tumor response on survival of patients treated with neoadjuvant mFOLFOX6 plus bevacizumab for the synchronous liver metastases from colorectal cancer.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 625-625
Author(s):  
Yu Katayose ◽  
Kazuyuki Ishida ◽  
Kei Nakagawa ◽  
Junichiro Yamauchi ◽  
Masaya Oikawa ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Resection ◽  
Liver Metastases ◽  
Initial Treatment ◽  
Tumor Response ◽  
University Hospital ◽  
Maximum Diameter ◽  
Tumor Regression Grade ◽  
Synchronous Liver Metastases ◽  
The Impact

625 Background: The synchronous liver metastases (SLM) from colorectal cancer (CRC) have a poor prognosis. Therefore, we conducted a phase II study of neoadjuvant mFOLFOX6 + bevacizumab for SLM to explore the appropriate initial treatment (BeFORE study). Here, assess the impact of histological tumor response (HR) on the relapse-free survival (RFS) and the overall survival (OS). Methods: The main inclusion criteria of BeFORE study were SLM within 10 nodules and with measurable disease. The primary endpoint was the response rate (RR). The secondary endpoints included R0-liver resection rate, HR, RFS and OS. Patients (pts) were enrolled after R0-resection of the primary CRC and received 8 courses of mFOLFOX6 + BV (the first and last courses were mFOLFOX6 alone). After this neoadjuvant chemotherapy, pts underwent resection of liver metastases within 4-8 weeks. HR was re-assessed on the basis of the tumor regression grade (TRG) which evaluates the extent of fibrosis of tumor cells, and the modified TRG which evaluates the extent of fibrosis and therapeutic-associated necrosis, using resected tumor samples. Results: Between June 2008 and November 2010, 47 pts were enrolled and 44 pts were treated per protocol. The median number of metastases was 2 nodules, and the maximum diameter of tumors was 12.9 cm. The overall RR was 72.7%. Forty pts underwent liver resection and 39 pts had the R0-liver resection. Five pts (12.5%) of resected 40 pts achieved TRG 1-2 (major HR), 5 pts (12.5%) had TRG 3 (partial HR) and 30 pts (75.0%) had TRG 4-5 (no HR). 8 pts (20.0%) achieved mTRG 1-2, 8 pts (20.0%) had mTRG 3, and 24 pts (60.0%) had mTRG 4-5. With a median follow-up of 35 months, the 2-year RFS rate was 27.3% (the median RFS was 10.5 months), and the 2-year OS rate was 88.4%. Here, we perform sub-group analyses of RFS and OS by TRG, mTRG, respectively. Conclusions: The impact of HR (TRG, mTRG) on survival could help us with considering about the appropriateness of neo-adjuvant mFOLFOX6 + BV as the initial treatment for SLM. (This trial is on University hospital Medical Information Network-Clinical Trials Registry (UMIN-CTR); UMIN000001568.) Clinical trial information: UMIN000001568.

Sign in / Sign up

Export Citation Format

Share Document